Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when AVR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAnteris launches up to $250M at-the-market offering to fund DurAVR heart valve development
Filed May 22, 2026 · Period ending May 22, 2026 · ~1 min read
Key Changes
-
high
Company established ability to sell up to $250 million of common stock through TD Securities at its discretion, potentially diluting existing shareholders over time as shares are sold into the market.
Item 1.01 verify on EDGAR → -
high
Proceeds will primarily fund ongoing development of DurAVR Transcatheter Heart Valve System, the company's core product, with remainder for working capital and general corporate purposes.
Item 1.01 verify on EDGAR → -
medium
TD Securities will receive 3% commission on gross proceeds from stock sales, with either party able to terminate the agreement upon ten days' notice.
Item 1.01 verify on EDGAR → -
low
Offering conducted under existing shelf registration statement filed January 2026 and declared effective by SEC on January 8, 2026.
Item 1.01 verify on EDGAR →
Summary
Anteris Technologies has established an at-the-market equity offering facility allowing it to raise up to $250 million by selling common stock through TD Securities over time. Unlike a traditional stock offering where shares are sold all at once, this ATM facility gives the company flexibility to sell shares gradually at its discretion through Nasdaq or negotiated transactions.
The capital raise signals the company needs substantial funding to advance its DurAVR Transcatheter Heart Valve System through development. For existing shareholders, this represents potential dilution as new shares enter the market, though the timing and amount of actual sales remain at management's discretion. The 3% commission to TD Securities is standard for such arrangements.
The company's decision to pursue this financing method rather than a traditional offering or debt suggests management wants flexibility to access capital as needed while development progresses. Investors should monitor subsequent 8-K filings and quarterly reports for disclosure of actual share sales under this agreement, which will reveal how aggressively management is tapping this facility and the resulting dilution impact.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Anteris entered an at-the-market equity offering agreement to sell up to $250M of common stock through TD Securities for DurAVR development.
Added in current filing · verify on EDGAR →
On May 22, 2026, Anteris Technologies Global Corp. (the “Company”) entered into a Sales Agreement (the “Agreement”) with TD Securities (USA) LLC (“TD Cowen”). Pursuant to the terms of the Agreement, the Company may offer and sell through TD Cowen, from time to time and at its sole discretion, shares of the Company’s common stock, par value of $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $250,000,000 (the “Offering”).
The company established an at-the-market equity offering facility allowing it to sell up to $250 million of common stock through TD Securities as sales agent. Sales will occur at the company's discretion over time through Nasdaq or negotiated transactions. TD Securities will receive a 3.0% commission on gross proceeds from sales where it acts as agent.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Sales Agreement, dated as of May 22, 2026, by and between Anteris Technologies Global Corp. and TD Securities (USA) LLC.
The company has entered into a sales agreement with TD Securities (USA) LLC dated May 22, 2026. This type of agreement typically allows the company to sell shares on an at-the-market basis, providing a mechanism for raising capital by issuing equity into the market over time. The filing includes a legal opinion from Jones Day regarding the validity of the shares that may be issued under this arrangement.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 27, 2026 · How we verify